Liposomal daunorubicin + cytarabarine valid for leukaemia?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1413, 2003-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New therapies for mature T-cell leukaemia?

Inpharma, Vol. 1, Iss. 1315, 2001-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Double-unit UCBT best for acute leukaemia?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 646, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Cytarabine/etoposide/ibritumomab tiuxetan Y-90: Treatment-related acute myeloid leukaemia?: case report

Reactions Weekly, Vol. 1, Iss. 1295, 2010-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Corticosteroids/mycophenolate mofetil/tacrolimus: Atypical acute leukaemia?: case report

Reactions Weekly, Vol. 1, Iss. 1290, 2010-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Disposition of Liposomal Daunorubicin During Cotreatment with Cytarabine in Patients with Leukaemia

By Pea F.

Clinical Pharmacokinetics, Vol. 42, Iss. 9, 2003-01 ,pp. : 851-862

Adis International

Access to resources Recommend Favorite